How do hospitals respond to price changes in emergency departments?


Journal

Health economics
ISSN: 1099-1050
Titre abrégé: Health Econ
Pays: England
ID NLM: 9306780

Informations de publication

Date de publication:
07 2019
Historique:
received: 24 04 2018
revised: 05 11 2018
accepted: 11 04 2019
entrez: 26 6 2019
pubmed: 27 6 2019
medline: 12 8 2020
Statut: ppublish

Résumé

Little is known about how prospective provider payment affects the provision of services led by unpredictable demand. We investigate hospital responses to a 32% increase in price for two treatments in emergency departments in England in April 2011 using data on 11,532,304 attendances (79 hospitals) between 2009/2010 and 2013/2014. We compare changes in the volumes of these two treatments to a treatment not attracting additional reimbursement using a difference-in-differences framework. Additional reimbursement led to 76% and 152% increases in the volumes of the two incentivised treatments. Hospitals received an additional £64.4 M between April 2011 and March 2014 for providing these treatments, of which 40% (£25.9 M) was attributable to the unanticipated hospital response to the price increase. We use time in treatment to distinguish real increases in treatment from reductions in undercoding or increases in upcoding. The association between the recorded receipt of these treatments and time spent in treatment was the same before and after the price increase, and there was no association between hospital-specific increases in recorded treatment volumes and changes in treatment times. The persistence of the treatment time increment suggests the increase in recorded treatment was a real increase in provision of treatments.

Identifiants

pubmed: 31237096
doi: 10.1002/hec.3890
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

830-842

Informations de copyright

© 2019 John Wiley & Sons, Ltd.

Auteurs

Beth Parkinson (B)

Health Organisation, Policy and Economics, School of Health Sciences, The University of Manchester, Manchester, UK.

Rachel Meacock (R)

Health Organisation, Policy and Economics, School of Health Sciences, The University of Manchester, Manchester, UK.

Matt Sutton (M)

Health Organisation, Policy and Economics, School of Health Sciences, The University of Manchester, Manchester, UK.
Melbourne Institute of Applied Economic and Social Research, Faculty of Business and Economics, The University of Melbourne, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH